David V Glidden1. 1. University of California, San Francisco, California, USA.
Abstract
PURPOSE OF REVIEW: This review considers statistical issues in the design and analysis of the studies used to develop long-acting formulations of antiretrovirals for pre-exposure prophylaxis (PrEP). RECENT FINDING: An abundant pipeline of products is maturing. Accelerating their evaluation as clinical products requires abandonment of noninferiority standards. Randomized trials should be based on the comparison of principled but innovative estimates of background HIV risk and enrich enrollment for those who do not desire current PrEP products. At every stage of testing, innovative analyses can be applied to help inform and accelerate later studies. SUMMARY: The development of new long-acting PrEP regimens can be accelerated by innovations in design, ingenuity in synthesizing data sources, and application of causal inference methods.
PURPOSE OF REVIEW: This review considers statistical issues in the design and analysis of the studies used to develop long-acting formulations of antiretrovirals for pre-exposure prophylaxis (PrEP). RECENT FINDING: An abundant pipeline of products is maturing. Accelerating their evaluation as clinical products requires abandonment of noninferiority standards. Randomized trials should be based on the comparison of principled but innovative estimates of background HIV risk and enrich enrollment for those who do not desire current PrEP products. At every stage of testing, innovative analyses can be applied to help inform and accelerate later studies. SUMMARY: The development of new long-acting PrEP regimens can be accelerated by innovations in design, ingenuity in synthesizing data sources, and application of causal inference methods.
Authors: Oliver Laeyendecker; Ron Brookmeyer; Matthew M Cousins; Caroline E Mullis; Jacob Konikoff; Deborah Donnell; Connie Celum; Susan P Buchbinder; George R Seage; Gregory D Kirk; Shruti H Mehta; Jacquie Astemborski; Lisa P Jacobson; Joseph B Margolick; Joelle Brown; Thomas C Quinn; Susan H Eshleman Journal: J Infect Dis Date: 2012-11-05 Impact factor: 5.226
Authors: Jennifer E Balkus; Elizabeth Brown; Thesla Palanee; Gonasagrie Nair; Zakir Gafoor; Jingyang Zhang; Barbra A Richardson; Zvavahera M Chirenje; Jeanne M Marrazzo; Jared M Baeten Journal: J Acquir Immune Defic Syndr Date: 2016-07-01 Impact factor: 3.731
Authors: Stephanie M Davis; Jonas Z Hines; Melissa Habel; Jonathan M Grund; Renee Ridzon; Brittney Baack; Jonathan Davitte; Anne Thomas; Valerian Kiggundu; Naomi Bock; Paran Pordell; Caroline Cooney; Irum Zaidi; Carlos Toledo Journal: BMJ Open Date: 2018-09-01 Impact factor: 2.692
Authors: J Gerardo García-Lerma; Ron A Otten; Shoukat H Qari; Eddie Jackson; Mian-Er Cong; Silvina Masciotra; Wei Luo; Caryn Kim; Debra R Adams; Michael Monsour; Jonathan Lipscomb; Jeffrey A Johnson; David Delinsky; Raymond F Schinazi; Robert Janssen; Thomas M Folks; Walid Heneine Journal: PLoS Med Date: 2008-02 Impact factor: 11.069
Authors: Michelle Cespedes; Moupali Das; J Carlo Hojilla; Jill Blumenthal; Karam Mounzer; Moti Ramgopal; Theo Hodge; Thiago S Torres; Charles Peterson; Senzokuhle Shibase; Ayana Elliott; A C Demidont; Larkin Callaghan; C Chauncey Watson; Christoph Carter; Alex Kintu; Jared M Baeten; Onyema Ogbuagu Journal: PLoS One Date: 2022-06-03 Impact factor: 3.752